Cargando…

Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma

BACKGROUND: Occult HBV infection (OBI) is defined by the persistence of HBV in the liver without serum HBsAg and HBVDNA. It represents a life-threatening event during immunosuppressive chemotherapies. An OBI occurs in approximately 18% of HBcAb + patients. International guidelines suggest surveillan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masarone, Mario, De Renzo, Amalia, La Mura, Vincenzo, Sasso, Ferdinando Carlo, Romano, Marco, Signoriello, Giuseppe, Rosato, Valerio, Perna, Fabiana, Pane, Fabrizio, Persico, Marcello
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938973/ https://www.ncbi.nlm.nih.gov/pubmed/24533834 http://dx.doi.org/10.1186/1471-230X-14-31

Ejemplares similares

HBsAb and HBcAb Have No Significant Effect on the Progression of SLE and RA
por: WANG, Fen, et al.
Publicado: (2017)

HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy
por: Malagnino, Vincenzo, et al.
Publicado: (2019)

HBcAb positivity increases the risk of postoperative complications after extended hemihepatectomy for hilar cholangiocarcinoma
por: Wang, Wen‐Qiang, et al.
Publicado: (2023)

Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years
por: Zhang, Xi, et al.
Publicado: (2021)

Hepatitis B sero-prevalence among hematology patients: importance of Anti-HbcAb and efficiency of antiviral prophylaxis
por: Kantar, Funda Ugur, et al.
Publicado: (2022)

Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(−)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis
por: Kuo, Meng Hsuan, et al.
Publicado: (2020)

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis
por: Morisco, Filomena, et al.
Publicado: (2014)

Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia
por: Toscanini, Federica, et al.
Publicado: (2011)

Prevalence of Cirrhosis/Advanced Fibrosis Among HBsAg-Negative and HBcAb-Positive US Adults: A Nationwide Population-Based Study
por: Huang, Shuai-Wen, et al.
Publicado: (2022)

Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy
por: Lin, Ying-Cheng, et al.
Publicado: (2021)

Risk of hepatitis B reactivation in HBsAg−/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta‐analysis
por: Hong, Xuezhi, et al.
Publicado: (2023)

HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients
por: Malagnino, Vincenzo, et al.
Publicado: (2020)

The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report
por: Lebano, Rita, et al.
Publicado: (2014)

Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers
por: Malagnino, Vincenzo, et al.
Publicado: (2021)

Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21
por: Giordano, Claudia, et al.
Publicado: (2023)

Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study
por: Federico, Alessandro, et al.
Publicado: (2015)

Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage
por: Masarone, Mario, et al.
Publicado: (2017)

HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort
por: Malagnino, Vincenzo, et al.
Publicado: (2021)

Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort
por: Malagnino, Vincenzo, et al.
Publicado: (2023)

Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study
por: Tien, Ya-Chih, et al.
Publicado: (2018)

NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome
por: Rosato, Valerio, et al.
Publicado: (2019)

Isolated Anti-HBc and Occult HBV Infection in Dialysis Patients
por: Ramezani, Amitis, et al.
Publicado: (2014)

The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights
por: Federico, Alessandro, et al.
Publicado: (2021)

Evaluation of Blood Units with Isolated Anti HBC for the Presence of HBV DNA
por: Zekri, Abdel-Rahman N., et al.
Publicado: (2002)

Occult HBV among Anti-HBc Alone: Mutation Analysis of an HBV Surface Gene and Pre-S Gene
por: Kim, Myeong Hee, et al.
Publicado: (2017)

Production of the HBc Protein from Different HBV Genotypes in E. coli. Use of Reassociated HBc VLPs for Packaging of ss- and dsRNA
por: Petrovskis, Ivars, et al.
Publicado: (2021)

Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
por: Masarone, Mario, et al.
Publicado: (2018)

Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets
por: Gravina, Antonietta Gerarda, et al.
Publicado: (2018)

Corrigendum to “Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease”
por: Masarone, Mario, et al.
Publicado: (2021)

Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients
por: Cerva, Carlotta, et al.
Publicado: (2022)

Correction to: “Non alcoholic fatty liver disease and eNOS dysfunction in humans”
por: Persico, Marcello, et al.
Publicado: (2017)

“Non alcoholic fatty liver disease and eNOS dysfunction in humans”
por: Persico, Marcello, et al.
Publicado: (2017)

Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience
por: Cerchione, Claudio, et al.
Publicado: (2016)

Seroprevalence of anti-HBc, risk factors of occupationally acquired HBV infection and HBV vaccination among hospital staff in Poland: a multicenter study
por: Ganczak, Maria, et al.
Publicado: (2019)

Prevalence of HBc-Ab among HBs-Ag negative healthy blood donors in south of Iran
por: Khorami, Farhad, et al.
Publicado: (2013)

Anti‐HBc‐nonreactive occult hepatitis B infections with HBV genotypes B and C in vaccinated immunocompetent adults
por: Deng, Xuelian, et al.
Publicado: (2022)

Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas
por: Lan, Ting-Yuan, et al.
Publicado: (2023)

Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody
por: Laksananun, Nattinee, et al.
Publicado: (2019)

Anti-HBc IgG Responses Occurring at the Early Phase of Infection Correlate Negatively with HBV Replication in a Mouse Model
por: Wang, Xuyang, et al.
Publicado: (2022)

RE: Risk of HBV Reactivation in HBsAg Negative and Anti-HBc IgG Positive Patients Receiving Biologic Therapy
por: Ergenç, İlkay, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lrp60607s6b1sl7k035cca9kgp